ACTA1 and keloid: The LA67-RL-Gel group had the least amount of CD31 and α-SMA, indicating that LA67-RL-Gel can reduce CD31 secretion, decrease α-SMA content, inhibit angiogenesis, and exert antifibrotic effects, thus treating keloids.